As Chinese innovative drug companies go global, cross-border licensing has become a key path to international markets, while companies also bring in overseas products and technologies. These deals often involve licensed rights, R&D division, milestone payments, and supply chains, raising complex tax issues. This session uses typical scenarios to sort out common tax controversies in license-out and license-in transactions, and explore supply chain implementation at the contracting stage, including:

1. How pharma collaboration models are changing;
2. License-out: Properly classifying taxes when Chinese innovation goes overseas;
3. License-in: Making cross-border payments work;
4. After the licensing deal: Structuring the supply chain;
5. From disputes to deal design: What companies should prepare.

We look forward to seeing your participation!